摘要
近年来,随着COX两种形式的发现和研究,人们逐渐认识到传统非甾体抗炎药的毒副作用是由于对COX两种形式酶无选择性抑制导致。因此,选择性COX-2抑制剂因其低毒副作用受到欢迎。为了更好地理解和应用非甾体类抗炎药,本文对COX-2抑制剂和传统非甾体抗炎药研究进展作一探讨。
同被引文献25
-
1鄢琳,井春梅,周杰明,肖爱丽,程刚,汤韧.选择性COX-2抑制剂的安全性评估[J].中国药物警戒,2005,2(1):16-20. 被引量:9
-
2American Society of Anesthesiologists Task Force on Acute Pain Management. Practice guidelines for acute pain manage ment in the perioperative setting[J]. Anesthesiology, 20!2, 116(2) :248-273.
-
3Hochberg M C, Aitman R D, April K T, eZ aZ. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoar- thrifts of the hand, hip, and knee[J].Arthritis Care Res, 2012,64(4) :465-474.
-
4Atchison J W, Herndon C M, Rusie E. NSAIDs for muscu-loskeletal pain management: current perspectives and novel strategies to improve safety[J]. J ManagCare Pharm,2013, 19(9 a) :3-19,.
-
5Brune K, Patrignani P. New insights into the use of currently available non steroidal anti-inflammatory drugs[J]. J Pain Res,2015,8:105-118.
-
6Martelli A, Testai L, Anzini M,et al. The novel anti-inflam matory agent VA694, endowed with both NO-releasing and COX-2 selective inhibiting properties, exhibits NO mediated positive effects on blood pressure, coronary flow and endothe- 1.ium in an experimental model of hypertension and endothelial dysfunction[J].Pharmacol Res, 2013,78: 1-9.
-
7Yamamoto T, Sakashita Y. COX 2 inhibitor prevents the development of hyperalgesia induced by in~trathecal NMDA or AMPA[J]. Neuroreport,1998,9(17):3869 -3873.
-
8Bombardier C,Laine L,Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis[J].N Engl J Med, 2000,343(21) : 1520-1528.
-
9Silverstein F E,Faich G,Goldstein J l.,et aZ. Gastrointestinal toxicity with celecoxib 'us nonsteroidal anti inflammatory drugs for osteoarthritis and rheumatoid arthritis: the (;I.ASS study:a randomi,ed controlled trial[J]. JAMA, 2000,284 (10) :1247-1255.
-
10Bhala N, Emberson J, Merhi A, et al. Vascular and upper gastrointestinal effects of non steroidal anti inflammatory drugs: recta-analyses of individual participant data from ran domized trials[J]. Lancet,2013,382(9894) :769-779.
二级引证文献22
-
1李旸,陈晨,方志文.吡罗昔康纳米结构脂质载体的制备及体外透皮特性研究[J].中国药师,2017,20(3):416-420. 被引量:5
-
2朱秋爽,梅仲秋,刘涛,赵军,由淑萍.新疆圆柏有效成分抑制COX-1/2、5-LO作用及对脂多糖诱导RAW264.7细胞释放TNF-α的影响[J].中国药理学通报,2018,34(2):295-296. 被引量:3
-
3胡海,雷孝勇,李华,陈恒安,徐祖健.金黄散治疗跟痛症临床研究[J].亚太传统医药,2018,14(1):193-195. 被引量:3
-
4董利薇,董国栋,曹建业,张峰,吴卫卫.环氧化酶2、血管内皮生长因子mRNA在异位骨化组织中的表达[J].临床合理用药杂志,2018,11(1):152-153. 被引量:4
-
5安宁,谢鹏,王敏,温洋,孙严,刘可柔.塞来昔布载药胶束的制备与大鼠体内药动学研究[J].解放军药学学报,2018,34(1):30-33. 被引量:1
-
6刘勇,王斌,陈思思.siRNA沉默胰腺癌BXPC-3细胞中Her-2/neu基因对COX-2表达水平及细胞增殖、凋亡、侵袭力的影响[J].临床和实验医学杂志,2018,17(10):1018-1021. 被引量:1
-
7王金云,张铁松,马帅茹,胡鸢,张丽,王晓晶,侯明岩,石秀秀.应用塞来昔布减轻唑来膦酸不良反应的临床效果观察[J].感染.炎症.修复,2017,18(4):234-235. 被引量:4
-
8宋卫军,袁景和,高东梅,吕德林.肩胛上神经阻滞治疗早期冻结肩的效果及其作用机制研究[J].西南国防医药,2018,28(9):876-878. 被引量:2
-
9沈宇凤,付金荣.中西医治疗慢性盆腔疼痛研究进展[J].江西中医药,2017,48(5):72-75. 被引量:12
-
10邱凯莎,黎霭云,徐秀娟.帕瑞昔布钠对腹腔镜下阑尾切除术患者术后疼痛及血清β-内啡肽、HSP70、IL-6水平的影响[J].中国医师杂志,2019,21(2):258-260. 被引量:9
-
1卢定强,沈东,凌岫泉.COX-2特异性抑制剂塞来昔布的合成研究进展[J].化工进展,2014,33(6):1521-1525. 被引量:7
-
2EMAMI, Saeed,FOROUMADI, Alireza.Synthesis of 4-(4-Methylsulfonylphenyl)-3-phenyl-2(3H)-thiazole Thione Derivatives as New Potential COX-2 Inhibitors[J].Chinese Journal of Chemistry,2006,24(6):791-794. 被引量:1
-
3侴晓玉,高娃,刘晓非.阿司匹林合成研究进展[J].呼伦贝尔学院学报,2016,24(6):82-84. 被引量:2
-
4杨昌英,刘义,李强国,李林蔚.三种非甾体类抗炎药与脂质体的相互作用[J].物理化学学报,2007,23(5):635-640. 被引量:7
-
5雷东升,许时.柠檬酸与硅线石、石英作用机理研究[J].有色金属,1995,47(1):24-27. 被引量:4
-
6吴琼,梅文杰,吴韦黎,陈燕华,曾玲莉,郑文杰.SiC管中微波辅助芳烃钌(Ⅱ)化合物[(η^6-C6H6)Ru(H2iiP)Cl]Cl的合成[J].高等学校化学学报,2013,34(8):1863-1867. 被引量:3
-
7彭涛,于静,严矛,李晓娟,陈冬东,代汉慧,国伟,李淑娟,唐英章.超高效液相色谱-电喷雾串联质谱法同时测定猪肝中非甾体类抗炎药残留[J].分析化学,2009,37(3):363-368. 被引量:12
-
8李顺来,郑艳,汪凤颖.新型1,5-二芳基咪唑类制剂的分子对接研究[J].北京化工大学学报(自然科学版),2006,33(4):75-79. 被引量:1
-
9马沙沙,张娅玲,张喜全,顾红梅,李宝林.5-甲基-4-[3-氯-4-(3-氟苄氧基)苯氨基]吡咯并三嗪-6-甲酸乙酯的合成及其抗肿瘤活性[J].化学研究与应用,2015,27(6):870-874.
-
10任会学,毛进隆.昔布类药物的心血管副作用研究综述[J].化工中间体,2006,2(1):1-5. 被引量:2